Securing the exemption from CVA charges in the new bank capital rules within the EU was a crucial element of the EACT's campaign to ensure that OTC derivatives continued to be available to corporates for risk management and that the pricing remained competitive. Policy in the United States towards the CVA exemption has been and remains a concern to the EACT. In March, the EACT Chairman wrote to Mr Daniel Pinto, Co-CEO Corporate & Investment at JP Morgan, to seek clarity on the position of the bank with respect to the EU CVA exemption and to ask what action has been undertaken by the bank in the last six months. In his response, Mr. Pinto stated that JP Morgan has not called for a repeal of the CVA exemption for corporate end users, yet also expressed concern that the approach by the regulators was not globally consistent and, as such, creates competitive inequalities.
Jean-Marc Servat, EACT, takes a deep dive into the world of crypto assets to discuss why Central Bank Digital Currencies (CBDCs) are capturing the attention of finance professionals.
View MoreThe latest issue contains the 2021 EACT Award, an interview with EACT Chair, Jean-Marc Servat, and more information about the upcoming Libor transition.
View MoreThe EACT has become a member of the Global Coalition to Fight Financial Crime (GCFFC).
View MoreAfter an exciting battle, the winner of the DACT Treasury Award 2020 has been announced.
View MoreView a recording of the recent webinar hosted by EACT and Loan Market Association (LMA).
View More